$NVAX
NOVAVAX INC Stock $nvax

$nvax Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000114420413060509 Filed on November 12, 2013

Income Statement

Concept	2013 Q4	2013 Q3	2012 Q3
Revenue	$8.748M	$4.802M	$5.765M
YoY Change	91.55%	-16.7%	15.12%
Cost Of Revenue	$2.600M	$2.276M	$3.838M
YoY Change	30.0%	-40.7%	75.25%
Gross Profit	$6.100M	$2.526M	$1.927M
YoY Change	134.62%	31.08%	-31.62%
Gross Profit Margin	69.73%	52.6%	33.43%
Selling, General & Admin	$4.100M	$3.900M	$2.100M
YoY Change	64.0%	85.71%	-22.22%
% of Gross Profit	67.21%	154.39%	108.98%
Research & Development	$16.30M	$13.95M	$6.642M
YoY Change	69.79%	110.0%	64.04%
% of Gross Profit	267.21%	552.18%	344.68%
Depreciation & Amortization	$1.000M	$600.0K	$400.0K
YoY Change	100.0%	50.0%	0.0%
% of Gross Profit	16.39%	23.75%	20.76%
Operating Expenses	$20.40M	$13.95M	$6.642M
YoY Change	68.6%	110.0%	64.04%
Operating Profit	-$14.30M	-$15.28M	-$6.849M
YoY Change	50.53%	123.08%	72.61%
Interest Expense	$0.00	$64.00K	$6.000K
YoY Change	-100.0%	966.67%	200.0%
% of Operating Profit
Other Income/Expense, Net	$200.0K	-$10.00K	$0.00
YoY Change
Pretax Income	-$14.10M	-$15.30M	-$7.217M
YoY Change	76.25%	112.0%	124.69%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$14.05M	-$15.30M	-$7.217M
YoY Change	75.68%	112.0%	124.69%
Net Earnings / Revenue	-160.65%	-318.62%	-125.19%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.410M	-$1.821M	-$1.075M
COMMON SHARES
Basic Shares Outstanding	208.5M shares	152.7M shares	133.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q4	2013 Q3	2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$133.1M	$146.4M	$28.40M
YoY Change	201.81%	415.49%	44.9%
Cash & Equivalents	$119.5M	$122.5M	$10.74M
Short-Term Investments	$13.60M	$23.90M	$17.70M
Other Short-Term Assets	$1.863M	$365.0K	$235.0K
YoY Change	989.47%	55.32%	-91.61%
Inventory
Prepaid Expenses	$3.044M	$3.016M	$2.807M
Receivables	$1.911M	$1.911M	$2.469M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$145.0M	$155.0M	$36.48M
YoY Change	187.65%	324.9%	38.72%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.25M	$13.97M	$9.815M
YoY Change	24.4%	42.32%	30.87%
Goodwill	$58.71M	$58.76M	$33.14M
YoY Change	77.14%	77.3%
Intangibles	$16.25M	$16.41M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$916.0K	$164.0K	$350.0K
YoY Change	160.97%	-53.14%	75.0%
Total Long-Term Assets	$90.12M	$90.05M	$44.06M
YoY Change	73.53%	104.38%	8.0%
TOTAL ASSETS
Total Short-Term Assets	$145.0M	$155.0M	$36.48M
Total Long-Term Assets	$90.12M	$90.05M	$44.06M
Total Assets	$235.1M	$245.1M	$80.55M
YoY Change	129.74%	204.27%	20.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.985M	$3.339M	$2.203M
YoY Change	85.41%	51.57%	-8.21%
Accrued Expenses	$10.41M	$9.553M	$6.031M
YoY Change	43.11%	58.4%	54.64%
Deferred Revenue
YoY Change
Short-Term Debt	$877.0K	$0.00	$0.00
YoY Change	-658.6%
Long-Term Debt Due	$1.000M	$700.0K	$200.0K
YoY Change	400.0%	250.0%
Total Short-Term Liabilities	$18.12M	$14.26M	$10.44M
YoY Change	55.22%	36.58%	55.84%
LONG-TERM LIABILITIES
Long-Term Debt	$1.200M	$1.900M	$1.000M
YoY Change	20.0%	90.0%	233.33%
Other Long-Term Liabilities	$1.763M	$1.578M	$7.700M
YoY Change		-79.51%	42.59%
Total Long-Term Liabilities	$1.763M	$1.578M	$8.700M
YoY Change		-81.86%	52.63%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.12M	$14.26M	$10.44M
Total Long-Term Liabilities	$1.763M	$1.578M	$8.700M
Total Liabilities	$31.89M	$28.50M	$19.17M
YoY Change	44.27%	48.67%	53.36%
SHAREHOLDERS EQUITY
Retained Earnings	-$410.1M	-$396.1M	-$350.1M
YoY Change	14.51%	13.13%
Common Stock	$2.091M	$2.090M	$1.360M
YoY Change	40.9%	53.68%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.450M	$2.450M	$2.450M
YoY Change	0.0%	0.0%
Treasury Stock Shares	455.4K shares	455.4K shares	$455.4K
Shareholders Equity	$203.2M	$216.6M	$61.38M
YoY Change
Total Liabilities & Shareholders Equity	$235.1M	$245.1M	$80.55M
YoY Change	129.74%	204.27%	20.04%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2012 Q3
OPERATING ACTIVITIES
Net Income	-$14.05M	-$15.30M	-$7.217M
YoY Change	75.68%	112.0%	124.69%
Depreciation, Depletion And Amortization	$1.000M	$600.0K	$400.0K
YoY Change	100.0%	50.0%	0.0%
Cash From Operating Activities	-$12.30M	-$14.90M	-$4.700M
YoY Change	284.37%	217.02%	38.24%
INVESTING ACTIVITIES
Capital Expenditures	-$1.000M	-$1.600M	-$1.100M
YoY Change	-52.38%	45.45%	450.0%
Acquisitions
YoY Change
Other Investing Activities	$10.20M	$17.00M	-$6.200M
YoY Change	-168.0%	-374.19%	-258.97%
Cash From Investing Activities	$9.200M	$15.40M	-$7.300M
YoY Change	-153.49%	-310.96%	-302.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	100.0K	119.3M	7.400M
YoY Change	-99.63%	1512.16%	722.22%
NET CHANGE
Cash From Operating Activities	-12.30M	-14.90M	-4.700M
Cash From Investing Activities	9.200M	15.40M	-7.300M
Cash From Financing Activities	100.0K	119.3M	7.400M
Net Change In Cash	-3.000M	119.8M	-4.600M
YoY Change	-145.45%	-2704.35%	-518.18%
FREE CASH FLOW
Cash From Operating Activities	-$12.30M	-$14.90M	-$4.700M
Capital Expenditures	-$1.000M	-$1.600M	-$1.100M
Free Cash Flow	-$11.30M	-$13.30M	-$3.600M
YoY Change	927.27%	269.44%	12.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001000694
CY2013Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	208510739	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	NOVAVAX INC
	dei	Trading Symbol TradingSymbol	NVAX
	nvax	Acquisition Transaction Costs AcquisitionTransactionCosts	1300000	USD
CY2011Q4	nvax	Additional Tenant Improvement Allowance AdditionalTenantImprovementAllowance	3000000	USD
	nvax	Business Acquisition Pro Forma Earnings Per Share Basic And Diluted BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted	-0.24
	nvax	Business Acquisition Pro Forma Earnings Per Share Basic And Diluted BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted	-0.18
CY2013Q3	nvax	Business Acquisition Pro Forma Earnings Per Share Basic And Diluted BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted	-0.09
CY2012Q3	nvax	Business Acquisition Pro Forma Earnings Per Share Basic And Diluted BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted	-0.06
CY2013Q3	nvax	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill	25298000	USD
	nvax	Capital Lease Obligation Equipment Purchased CapitalLeaseObligationEquipmentPurchased		USD
	nvax	Capital Lease Obligation Equipment Purchased CapitalLeaseObligationEquipmentPurchased	399000	USD
CY2008Q3	nvax	Common Shares Per Unit CommonSharesPerUnit	1	shares
	nvax	Deposits For Acquisition Of Property And Equipment DepositsForAcquisitionOfPropertyAndEquipment		USD
	nvax	Deposits For Acquisition Of Property And Equipment DepositsForAcquisitionOfPropertyAndEquipment	500000	USD
CY2013Q3	nvax	Loan Agreement Future Minimum Payments Due LoanAgreementFutureMinimumPaymentsDue	1681000	USD
CY2013Q3	nvax	Loan Agreement Future Minimum Payments Due In Year Three LoanAgreementFutureMinimumPaymentsDueInYearThree	396000	USD
CY2013Q3	nvax	Loan Agreement Future Minimum Payments Due In Year Two LoanAgreementFutureMinimumPaymentsDueInYearTwo	571000	USD
CY2013Q3	nvax	Loan Agreement Future Minimum Payments Next Twelve Months LoanAgreementFutureMinimumPaymentsNextTwelveMonths	571000	USD
CY2013Q3	nvax	Loan Agreement Future Minimum Payments Remainder Of Fiscal Year LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear	143000	USD
CY2013Q3	nvax	Novavax Shares Issued NovavaxSharesIssued	15600000	shares
	nvax	Reclassification From General Administrative Expenses To Research Development Expenses ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses	600000	USD
CY2012Q3	nvax	Reclassification From General Administrative Expenses To Research Development Expenses ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses	200000	USD
	nvax	Reclassification Of Restricted Cash From Financing Activities To Operating Activities ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities	800000	USD
	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration	1182000	USD
	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration	182000	USD
CY2013Q3	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration	534000	USD
CY2012Q3	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration	182000	USD
	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	5000000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	6100000	USD
CY2012Q4	us-gaap	Assets Assets	102345000	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	155020000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	50408000	USD
CY2013Q3	nvax	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Forfeiture Rate SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate	0.2315	pure
CY2012Q3	nvax	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Forfeiture Rate SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate	0.2315	pure
CY2011Q4	nvax	Tenant Improvement Allowance TenantImprovementAllowance	2500000	USD
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3339000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3228000	USD
CY2013Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1911000	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1011000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-326000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments		USD
CY2013Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9553000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7275000	USD
CY2013Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1113000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	430000	USD
CY2013Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	611913000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	438939000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1784000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1668000	USD
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	663000	USD
CY2012Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	493000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12157634	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12951625	shares
CY2013Q3	us-gaap	Assets Assets	245074000	USD
CY2013Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	23917000	USD
CY2012Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	32945000	USD
CY2013Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	23312000	USD
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	32515000	USD
CY2013Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	23917000	USD
CY2012Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	26712000	USD
	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	605000	USD
CY2012	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	430000	USD
	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss		USD
CY2012	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss		USD
CY2013Q3	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent		USD
CY2012Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	6233000	USD
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-40565000	USD
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-25033000	USD
CY2013Q3	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-15687000	USD
CY2012Q3	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-8490000	USD
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	14195000	USD
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	19530000	USD
CY2013Q3	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	4869000	USD
CY2012Q3	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	6272000	USD
CY2013Q3	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	41964000	USD
CY2013Q3	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	41942000	USD
CY2013Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Capital Lease Obligation BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation	94000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3366000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10738000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	105094000	USD
CY2013Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	3056000	USD
CY2013Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets	1092000	USD
CY2013Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	603000	USD
CY2013Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	2784000	USD
CY2013Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	16380000	USD
CY2013Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Long Term Debt BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt	193000	USD
CY2013Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther	1559000	USD
CY2013Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	165000	USD
CY2013Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	41964000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	407000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1365000	USD
CY2013Q3	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	115000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	58000	USD
CY2013Q3	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	222000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	237000	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	3034000	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition		USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	122493000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17399000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14104000	USD
CY2008Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	3.62
CY2008Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	0.5	shares
CY2008Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3343325	shares
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	208509739	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	147943317	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	208965169	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	148398747	shares
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	2090000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	1484000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37246000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20268000	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14824000	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7121000	USD
	us-gaap	Contract Revenue Cost ContractRevenueCost	5619000	USD
	us-gaap	Contract Revenue Cost ContractRevenueCost	12740000	USD
CY2013Q3	us-gaap	Contract Revenue Cost ContractRevenueCost	2276000	USD
CY2012Q3	us-gaap	Contract Revenue Cost ContractRevenueCost	3838000	USD
	us-gaap	Contracts Revenue ContractsRevenue	10985000	USD
	us-gaap	Contracts Revenue ContractsRevenue	17328000	USD
CY2013Q3	us-gaap	Contracts Revenue ContractsRevenue	4268000	USD
CY2012Q3	us-gaap	Contracts Revenue ContractsRevenue	5583000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	41942000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		USD
	us-gaap	Costs And Expenses CostsAndExpenses	50348000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	37680000	USD
CY2013Q3	us-gaap	Costs And Expenses CostsAndExpenses	20081000	USD
CY2012Q3	us-gaap	Costs And Expenses CostsAndExpenses	12614000	USD
CY2012Q3	us-gaap	Debt Instrument Basis Spread On Variable Rate1 DebtInstrumentBasisSpreadOnVariableRate1	0.1168	pure
CY2013Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2000000	USD
	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.121	pure
CY2012Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage Rate Range Minimum DebtInstrumentInterestRateStatedPercentageRateRangeMinimum	0.121	pure
	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	34529	USD
CY2012Q3	us-gaap	Debt Instrument Term DebtInstrumentTerm	P42M
CY2013Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	466000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	432000	USD
CY2013Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8287000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	6940000	USD
CY2013Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1084000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents		USD
CY2013Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	4700000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y6M
CY2008Q3	us-gaap	Equity Issuance Per Share Amount EquityIssuancePerShareAmount	2.68
CY2013Q3	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.2	pure
CY2013Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	190000	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	258000	USD
CY2013Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2500000	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2500000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1636000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1216000	USD
CY2013Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		USD
CY2012Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	267000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	16000	USD
CY2013Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	181000	USD
CY2013Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1084000	USD
CY2013Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1084000	USD
CY2013Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1084000	USD
CY2013Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	271000	USD
CY2013Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1084000	USD
CY2013Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16586000	USD
CY2013Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	16405000	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	267000	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-401000	USD
CY2013Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax		USD
CY2012Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-401000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	37000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	26000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10740000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7670000	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3857000	USD
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2134000	USD
CY2013Q3	us-gaap	Goodwill Goodwill	58759000	USD
CY2012Q4	us-gaap	Goodwill Goodwill	33141000	USD
CY2011Q4	us-gaap	Goodwill Goodwill	33141000	USD
CY2012Q3	us-gaap	Goodwill Goodwill	33141000	USD
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	25298000	USD
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod		USD
	us-gaap	Goodwill Translation Adjustments GoodwillTranslationAdjustments	320000	USD
	us-gaap	Goodwill Translation Adjustments GoodwillTranslationAdjustments		USD
CY2011Q1	us-gaap	Government Contract Receivable GovernmentContractReceivable	179000000	USD
CY2013Q3	us-gaap	Government Contract Receivable Unbilled Amounts GovernmentContractReceivableUnbilledAmounts	3194000	USD
CY2012Q4	us-gaap	Government Contract Receivable Unbilled Amounts GovernmentContractReceivableUnbilledAmounts	1570000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-37907000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-20472000	USD
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-15300000	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-7217000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2012Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	623000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-304000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	291000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	504000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-199000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	803000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	703000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	2803000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-639000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	271000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-862000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	838000	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	1624000	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-111000	USD
CY2013Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	16405000	USD
CY2012Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		USD
	us-gaap	Interest Expense InterestExpense	132000	USD
	us-gaap	Interest Expense InterestExpense	12000	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	64000	USD
CY2012Q3	us-gaap	Interest Expense InterestExpense	6000	USD
	us-gaap	Interest Paid InterestPaid	120000	USD
	us-gaap	Interest Paid InterestPaid		USD
	us-gaap	Investment Income Net InvestmentIncomeNet	149000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	111000	USD
CY2013Q3	us-gaap	Investment Income Net InvestmentIncomeNet	53000	USD
CY2012Q3	us-gaap	Investment Income Net InvestmentIncomeNet	39000	USD
CY2013Q3	us-gaap	Liabilities Liabilities	28500000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	22105000	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	245074000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	102345000	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	14260000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11675000	USD
CY2013Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	1653000	USD
CY2012Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	753000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"> Note 1 - Organization</p> <p style="FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in">  </p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Novavax, Inc. ("Novavax," and together with its subsidiary, "Novavax AB," the "Company") is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant protein nanoparticle vaccines and adjuvants. The Company's product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for seasonal influenza, pandemic influenza and respiratory syncytial virus ("RSV").</p> <!--EndFragment--></div> </div>
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	130943000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	400000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	204000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26758000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7231000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15147000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33096000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14977000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-37929000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20472000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-15300000	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-7217000	USD
CY2013Q3	us-gaap	Notes Payable Current NotesPayableCurrent	597000	USD
CY2012Q4	us-gaap	Notes Payable Current NotesPayableCurrent	157000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-38181000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20170000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-15279000	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6849000	USD
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Receivable OperatingLeasesFutureMinimumPaymentsReceivable	1900000	USD
CY2013Q3	us-gaap	Other Assets Current OtherAssetsCurrent	365000	USD
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	171000	USD
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	164000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	351000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	509000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent		USD
CY2013Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	509000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent		USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	683000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	204000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	476000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	96000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	174000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-33000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	96000	USD
CY2013Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1578000	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent		USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-678000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-436000	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	10000	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		USD
CY2013Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	10000	USD
CY2012Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		USD
	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	700000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	14754000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	15763000	USD
CY2013Q3	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	22000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	4762000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	2202000	USD
CY2013Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2013Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q3	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3016000	USD
CY2012Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2559000	USD
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"> <strong><em>Reclassifications</em></strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in">  </p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Overhead expenses relating to supply chain management of $0.2 million and $0.6 million for the three and nine months ended September 30, 2012, respectively, have been reclassified from general and administrative expenses to research and development expenses. Also, within the September 30, 2012 statement of cash flows, restricted cash received of $0.8 million recorded in financing activities has been reclassified and is included in operating activities. These reclassifications have been made to conform to current year presentation.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in">  </p> <!--EndFragment--></div> </div>
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	128659000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	26925000	USD
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	1500000	USD
CY2008Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	17500000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1450000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	650000	USD
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-305000	USD
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-20000	USD
	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	-1000	USD
	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	-756000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	23630000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	2500000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	83000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	318000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1194000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	49000	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13969000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11456000	USD
CY2013Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	757000	USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	756000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	54000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	90000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33989000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17270000	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13948000	USD
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6642000	USD
CY2013Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	124000	USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	986000	USD
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-396092000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-358163000	USD
	us-gaap	Revenues Revenues	12167000	USD
	us-gaap	Revenues Revenues	17510000	USD
CY2013Q3	us-gaap	Revenues Revenues	4802000	USD
CY2012Q3	us-gaap	Revenues Revenues	5765000	USD
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation ShareBasedCompensation	1784000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1668000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	33334	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	33334	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.39
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.39
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2013Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y3M
CY2012Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y2M27D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.7372	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8048	pure
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.6251	pure
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.7671	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5581	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7547	pure
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5675	pure
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.766	pure
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0055	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0136	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0154	pure
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0136	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0054	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0055	pure
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0112	pure
CY2013Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	5500000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y10M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	300000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.02
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.71
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.41
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.09
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	15900000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	216574000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	80240000	USD
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	12600000	shares
CY2008Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6686650	shares
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	34000000	USD
CY2013Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	455430	shares
CY2012Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	455430	shares
CY2013Q3	us-gaap	Treasury Stock Value TreasuryStockValue	2450000	USD
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2450000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> <strong><em>Use of Estimates</em></strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in">  </p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these estimates.</p> <!--EndFragment--></div> </div>
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	156555	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	127246	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	168537	shares
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	134178	shares

Files In Submission

Name	View Source	Status
0001144204-13-060509-index-headers.html	Edgar Link	pending
0001144204-13-060509-index.html	Edgar Link	pending
0001144204-13-060509.txt	Edgar Link	pending
0001144204-13-060509-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
nvax-20130930.xml	Edgar Link	completed
nvax-20130930.xsd	Edgar Link	pending
nvax-20130930_cal.xml	Edgar Link	unprocessable
nvax-20130930_def.xml	Edgar Link	unprocessable
nvax-20130930_lab.xml	Edgar Link	unprocessable
nvax-20130930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v358320_10q.htm	Edgar Link	pending
v358320_ex31-1.htm	Edgar Link	pending
v358320_ex31-2.htm	Edgar Link	pending
v358320_ex32-1.htm	Edgar Link	pending
v358320_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVAX
NOVAVAX INC Stock $nvax

2013 Q4 Form 10-Q Financial Statement

#000114420413060509 Filed on November 12, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX NOVAVAX INC Stock $nvax

2013 Q4 Form 10-Q Financial Statement

#000114420413060509 Filed on November 12, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX
NOVAVAX INC Stock $nvax